Upper Tract Urothelial Carcinoma

Overview

Upper tract urothelial carcinoma (UTUC) refers to urothelial tumours arising from the lining of the renal calyces, renal pelvis, or ureter. It is uncommon, so outcome data are limited. Panurothelial disease describes disease involving the bladder plus two extravesical sites — in males this may include one or both upper tracts and/or the prostatic urethra; in females, the bladder plus both upper tracts.

Epidemiology

• Incidence — relatively rare: ~2/100,000 person-years (~7,000 US cases/year). Renal pelvis tumours are slightly more common than ureteral (1.2 vs 0.8/100,000). Ureteral tumours favour the lower ureter (70%) over the mid (25%) and upper (5%) ureter, likely reflecting downstream implantation. Incidence is higher in Balkan countries.
• Age — peak in the 70s–80s (older than bladder cancer). Presentation at <60 years should raise concern for hereditary UTUC (Lynch syndrome).
• Sex — M:F 2:1 (vs 4:1 for bladder cancer).
• Race — US Whites are ~2× more likely than Blacks to develop UTUC.

Risk Factors

Hereditary — Lynch syndrome (HNPCC): accounts for 7–20% of US cases. Affected patients are younger (mean 55 years) and more often female.

Acquired — shared with bladder cancer:

• Cigarette smoking — the most important modifiable risk factor; cessation lowers subsequent risk.
• Occupational exposure — aromatic hydrocarbons (chemical, petrol, plastic industries; coal, asphalt, tar).
• Chronic inflammation/infection/iatrogenesis — chronic infection with stones/obstruction is linked to squamous cell carcinoma (less often adenocarcinoma).
• Alkylating chemotherapy — cyclophosphamide or ifosfamide.
• Analgesic abuse — phenacetin is best described (also codeine, acetaminophen, aspirin); cases have fallen since phenacetin was replaced by acetaminophen.
• Arsenic — e.g. artesian-well drinking water.
• History of bladder cancer — most UTUC are secondary tumours presenting after NMIBC; still, only 2–4% of bladder cancer patients later develop UTUC (interval 17–170 months). Bladder cancer after UTUC is more common than the reverse (downstream seeding, longer carcinogen exposure, greater urothelial cell number).

Acquired — unique to UTUC: aristolochic acid (Aristolochia fangchi and A. clematitis) — mutagenic; implicated in Balkan endemic nephropathy and Chinese herb nephropathy. These plants grow as weeds in Balkan wheat fields; Balkan endemic nephropathy incidence is falling.

Risk factors for subsequent UTUC after cystectomy for bladder cancer: low-grade tumours, non–muscle-invasive tumours, presence of CIS, multiple urothelial recurrences, multifocal tumours, prior UTUC, positive ureteral margin, and prostatic/female urethral involvement (Picozzi 2012 meta-analysis, 27 studies, 13,185 patients). Long-term upper-tract surveillance is therefore important in bladder cancer patients.

Embryology

The bladder is derived from endoderm; the ureter and renal pelvis are derived from mesoderm.

Histology

The upper-tract urothelium resembles that of the bladder except for a markedly thinner muscle layer and proximal abutment of the urothelium to the renal parenchyma. The urothelial layer is continuous from the calyces to the distal ureter and may extend into the collecting ducts (raising the possibility that collecting-duct renal cancers are related to urothelial cancers). The calyceal/pelvic walls have fibrous tissue and two smooth-muscle layers; the ureter's three muscle layers merge with the bladder's three.

Benign / pre-malignant:

• Papillomas and inverted papillomas — generally benign but associated with synchronous/metachronous UTUC; follow inverted papilloma for ≥2 years.
• Von Brunn nests — reactive proliferation, a variant of normal urothelium.
• Metaplasia and dysplasia — UTUC often progresses hyperplasia → dysplasia → CIS.

Malignant:

• Urothelial carcinoma — 90% of upper-tract tumours. Histologically similar to bladder UC, but the thin muscle layer may allow earlier invasion; UTUC is more often invasive and poorly differentiated, though stage-matched outcomes are comparable to bladder UC. Reported variants (squamous, glandular, sarcomatoid, micropapillary, neuroendocrine, lymphoepithelial) are aggressive but — unlike bladder cancer — variant histology has not independently predicted poor outcome after adjusting for clinicopathologic features.
• Squamous cell carcinoma — associated with chronic inflammation, infection, and analgesic abuse; typically more aggressive at presentation; ~6× more common in the renal pelvis than ureter.
• Adenocarcinoma — rare; associated with chronic inflammation, calculi, and chronic obstruction.

Diagnosis and Staging

TNM Staging (AJCC 8th edition)

T stage	Definition
Ta	Non-invasive papillary carcinoma (confined to mucosa)
Tis	Carcinoma in situ
T1	Invades lamina propria (subepithelial connective tissue)
T2	Invades muscle
T3	Renal pelvis — beyond muscularis into peripelvic fat or renal parenchyma; ureter — beyond muscularis into periureteric fat
T4	Invades adjacent organs, or through the kidney into perinephric fat

N stage: N0 (none); N1 (single node ≤2 cm); N2 (single node >2 cm, or multiple nodes). M stage: M0 / M1 (distant metastasis).

Natural History

At diagnosis, ~25% present as localized disease, >50% as regionally advanced, and ~20% as distant disease. Most occur in a single renal unit; synchronous bilateral UTUC is rare (<2%), but CIS increases the risk of bilateral and multifocal disease. Metachronous recurrence is ~80% after bladder cancer and 2–6% after contralateral UTUC. Spread routes:

• Lymphatic (depth-dependent) — renal pelvis/upper ureter drain to hilar then para-aortic/paracaval nodes; distal ureteral tumours drain to pelvic nodes.
• Hematogenous — most often liver, lung, and bone.
• Epithelial seeding — antegrade (more common; explains recurrence in a ureteral stump left after incomplete ureterectomy) and retrograde.

Diagnosis and Evaluation

Per the 2023 AUA UTUC guidelines, work-up includes a personal/family history (to identify Lynch syndrome), labs (selective ipsilateral upper-tract cytology and eGFR/serum creatinine), CT urography, cystoscopy, upper-tract endoscopy with biopsy, and universal histologic testing (IHC or microsatellite instability). FISH and retrograde pyelography are optional.

History and physical — the most common presenting sign is hematuria; flank pain is second (usually dull from gradual obstruction, occasionally colicky from clot passage). Many are asymptomatic, found incidentally. A personal/family history positive for Lynch-associated disease warrants genetic counselling referral and raises the possibility of contralateral involvement.

Labs:

• Selective ipsilateral upper-tract cytology supplements biopsy — high-grade cytology with a low-grade biopsy suggests higher-risk features were missed. High specificity (~90% selective) but low sensitivity (~50%), directly related to grade; reported by the 7-category Paris System. Collect before contrast (contrast and inflammation/stones cause false positives). Selective collection (barbotage or saline washings) is preferred over voided cytology to improve yield, avoid contamination from bladder/urethral disease, and avoid dilution from the normal contralateral unit.
• Renal function — serum creatinine/eGFR (MDRD or CKD-EPI); split-function testing if refined assessment is needed. With obstructing tumours, decompress (ureteric stent preferred over nephrostomy, which risks tract seeding) and rehydrate for 7–14 days before rechecking eGFR; contralateral atrophy can cause over-estimation of post-op function.

Imaging:

• Multiphase CT with excretory-phase urography is preferred (pooled sensitivity 92%, specificity 95%). If contrast-enhanced CT is contraindicated (e.g. eGFR <30, untreatable iodine allergy), use MR urography (less sensitive, similar specificity); if both are contraindicated, use retrograde pyelography with non-contrast axial imaging (US). Typical findings: radiolucent filling defect, non-visualization of the collecting system, obstruction. UTUC enhances on the arterial/early-nephrographic phase and is dark on the urographic phase, with more infiltrative features than RCC.

Differential of an upper-tract filling defect
Tumour (UTUC, RCC, renal lymphoma, fibroepithelial polyp); blood clot; suburothelial hemorrhage; stone (higher HU than UC); renal papillary necrosis/sloughed papilla; hypertrophied papilla; inflammation; fungus ball; tuberculosis; polyureteritis cystica; retroperitoneal fibrosis

• Metastatic staging — chest X-ray; bone scan only if bone pain, hypercalcemia, or elevated alkaline phosphatase; PET is not routine (selective use when contrast CT/MRI cannot be obtained).

Cystoscopy is mandatory (most UTUC associate with bladder cancer).

Upper-tract endoscopy ± biopsy allows direct visualization and biopsy. Indications: a radiographic mass/urothelial thickening, lateralizing hematuria, or suspicious selective cytology. It may be omitted when findings would not change management (severe comorbidity, or diagnosis already clear from HG cytology plus convincing imaging). Biopsy is by ureteroscopic forceps or fluoroscopic retrograde brush; small instruments limit specimen size, so the urologist's visual grade impression is correct only ~70% of the time. Diagnostic accuracy (Subiela 2020 meta-analysis, 23 studies, 2,232 patients): PPV for muscle-invasive 94%, NPV for non-invasive 60%; HG match 97%, LG match 66%; overall 32% undergrading and 46% understaging. Avoid scoping a normal contralateral tract (seeding/injury risk). Perforation risks extra-urinary seeding — stop and stent/decompress if it occurs; pre-stenting reduces injury risk.

• Universal histologic testing (IHC, microsatellite instability) identifies Lynch-associated/MSI-high tumours — relevant for checkpoint-inhibitor and cisplatin sensitivity and for germline testing.
• Percutaneous biopsy is safe/effective for lesions not amenable to endoscopic biopsy.

Positive upper-tract cytology with no visible lesion — first repeat to confirm (infection/stones cause false positives); then CT urography and cystoscopy. Treat a bladder tumour if found; if cytology stays positive after a negative/treated bladder, evaluate extravesical sites with selective cytologies (and prostatic urethral sampling in men) plus ureteropyeloscopy. Upper-tract CIS is a presumptive diagnosis made by unequivocally positive selective cytology in the absence of radiographic/endoscopic findings.

Risk Stratification of Localized UTUC

The 2023 AUA guideline stratifies into low- vs high-risk of progression/≥pT2 disease, based primarily on biopsy grade (HG biopsy predicts ≥pT2: PPV 60%, NPV 77%), then sub-stratified favorable vs unfavorable using:

• Cytology;
• Radiographic appearance — multifocality, size, invasive features (heterogeneous texture suggests invasion), urinary obstruction, locoregional progression (suspicious nodes), and metastatic disease;
• Endoscopic appearance — sessile/papillary/flat, multifocality, and size (tumours ≥1.5 cm carry >80% risk of invasive disease);
• Lower-tract involvement — panurothelial disease (prior cystectomy, concomitant/metachronous lower-tract UC, or contralateral UTUC).

Management

Non-metastatic Disease

Four options, classified as nephron-sparing vs not (or surgical vs non-surgical removal):

Nephron-sparing	Non–nephron-sparing
Endoscopic ablation/resection (ureteroscopic or percutaneous); intraluminal therapy; segmental ureterectomy	Radical nephroureterectomy with bladder cuff excision

Nephron-sparing approaches carry a high risk of local recurrence and require vigilant follow-up.

Endoscopic ablation/resection — minimally invasive and renal-sparing, but with a high recurrence risk and residual risk of progression (imaging/biopsy under-stage). Choose retrograde (ureteroscopic) when tumour size, number, and access allow complete ablation; choose percutaneous antegrade for larger tumours, tumours hard to reach retrograde, or after prior cystectomy/diversion.

• Retrograde — lower morbidity, maintains a closed system; limited by small instruments (poorer biopsy/staging) and inability to reach some calyces (e.g. lower pole).
• Antegrade — larger instruments (more tumour removed, deeper biopsies), reaches difficult calyces, and the nephrostomy tract allows second-look nephroscopy and topical therapy; but higher morbidity, tract risks, usually inpatient, and possible (uncommon) tract seeding. A second-look nephroscopy is done 4–14 days later.
• Tumour size — <1.5 cm is optimal for ablation; ≥1.5 cm carries >80% invasive risk (ablation still possible based on experience/need for kidney sparing).
• Energy — laser (thulium, holmium, Nd:YAG) or electrocautery (small Bugbee; avoid circumferential fulguration → stricture).
• Ureteral access sheath — visualize the whole ureter first; allows repeated passage, fluid egress (lowers pelvicalyceal pressure), and lower intravesical recurrence (observational).
• Outcomes (Cutress 2012 systematic review, 34 studies) — 5-yr recurrence-free survival 13–54%, renal preservation 85%, cancer-specific survival 49–89%, OS 57–75%; outcomes worsen with grade. Repeat endoscopic evaluation within ~3 months (residual/recurrent disease is common), then at 3-month intervals until no disease.

Intraluminal therapy — indications: adjuvant after ablation, primary treatment of CIS, and primary treatment of low-grade UTUC (UGN-101).

• Adjuvant chemotherapy (thiotepa or mitomycin) — extrapolated from immediate intravesical chemo after TURBT; confirm no perforation first; delivered antegrade (nephrostomy), retrograde (ureteral catheter), or by bladder instillation with reflux via a double-J stent.
• Pelvicalyceal BCG — may be offered after complete ablation of high-risk favorable UTUC or for upper-tract CIS; imperative indications are solitary kidney, bilateral UTUC, or risk of ESRD; 6-week induction. (Foerster 2019: for CIS, RFS 84%.) The most common complication of intraluminal therapy is bacterial sepsis.
• UGN-101 (mitomycin + reverse-thermosensitive polymer; Jelmyto/Mitogel) — gels at body temperature to prolong dwell time, overcoming poor urothelial exposure. OLYMPUS (phase 3, n=71, primary/recurrent LG UTUC 5–15 mm): ~60% complete response at 3 months, ~60% of responders maintained at 12 months; adverse events common (94% any, 37% serious), 44% ureteric stenosis, 20% renal dysfunction. Carries an FDA label warning for ureteral obstruction, bone marrow suppression, and embryo-fetal toxicity.

Treatment selection by risk (AUA):

Risk group	Preferred approach
Low-risk, favorable	Tumour ablation (preferred when feasible); chemoablation (UGN-101) if complete ablation not feasible
Low-risk, unfavorable	Ablation (optional for low-volume tumours or those who cannot undergo RNU) or surgical removal (RNU/segmental)
High-risk, favorable	Surgical removal preferred; ablation only in rare select patients (low-volume or cannot undergo RNU)
High-risk, unfavorable	Surgical removal. RNU with complete bladder cuff excision + lymphadenectomy is the standard of care for high-risk UTUC. Distal ureterectomy with reimplant is preferred for HR/unfavorable-LR disease confined to the lower ureter in a functional renal unit

The surgical procedures are detailed on the Nephroureterectomy and Segmental Ureterectomy pages.

Lymph node dissection — no RCTs; recommended for high-risk UTUC (non-randomized evidence of oncologic benefit), optional for low-risk. Template by location: pyelocaliceal/proximal — ipsilateral great-vessel nodes from renal hilum to the inferior mesenteric artery (proximal ⅔ ureter to the aortic bifurcation); distal ⅓ ureter — ipsilateral pelvic nodes (at minimum obturator and external iliac).

Perioperative intravesical chemotherapy — a single dose after RNU or ureterectomy reduces bladder recurrence. ODMIT-C (n=284): a single post-op intravesical MMC dose (40 mg in 40 mL) at catheter removal reduced first-year bladder tumour risk by 11% (16% with MMC vs 27% with standard management). Gemcitabine is often preferred over MMC (risk of chemical peritonitis with extravasation).

Systemic Therapy

• Neoadjuvant chemotherapy — no RCTs, but cisplatin-based NAC should be offered for high-risk UTUC, especially when post-op eGFR is expected <60 or comorbidities would preclude post-op cisplatin (since RNU worsens renal function and cisplatin eligibility). A phase II trial (n=30, HG UTUC, 4 cycles neoadjuvant MVAC) gave a 14% pathologic complete response; a 2020 meta-analysis found pooled pCR 11% and partial response 43%. Non-cisplatin alternatives are not recommended neoadjuvantly outside trials.
• Adjuvant chemotherapy — platinum-based adjuvant chemo for advanced pathology (pT2–T4 N0–N3 M0 or pTanyN1–3 M0) not given NAC. POUT (phase 3, n=260, pT2–T4/N+): 4 cycles gemcitabine-cisplatin (gem-carbo if GFR 30–49) improved 3-year disease-free survival by 21% (71% vs 46%, HR 0.45) and metastasis-free survival; carboplatin and node-positive subgroups did worse.
• Adjuvant immunotherapy — CheckMate 274 (adjuvant nivolumab, n=709, ~20% UTUC) improved disease-free survival (21 vs 11 months overall); benefit was greater with PD-L1 ≥1%, but the UTUC subgroup hazard ratio favoured placebo. Adjuvant platinum chemotherapy is preferred over nivolumab for eligible patients who did not receive NAC; nivolumab is reserved for cisplatin-ineligible/refusing patients or high-risk pathology after NAC.
• Radiation — RNU alone gives high local control; adjuvant radiation without chemotherapy does not prevent distant failure; combined chemoradiation may have a role in advanced disease with adverse features.

Special Scenarios and Advanced Disease

• Upper-tract CIS — usually a diagnosis of exclusion (persistent positive selective cytology without endoscopic/radiographic findings). Management is not well established; most experience is with BCG via nephrostomy. Historical RNU for an isolated unilateral cytologic abnormality is no longer recommended (cytology false positives; high future bilateral risk), but observation alone is also inappropriate given repeated abnormal cytology.
• Watchful waiting/surveillance — for select patients with significant comorbidity/competing mortality risk or significant ESRD/dialysis risk from intervention; counsel about bleeding, obstruction, infection, and pain.
• Clinically node-positive (N+) — treat first with systemic therapy; consolidative RNU/ureterectomy with LND in responders.
• Distant metastatic (M+) — systemic therapy (± palliative radiation); RNU/ureterectomy is not initial therapy and has no cytoreductive benefit. MVAC (methotrexate, vinblastine, doxorubicin, cisplatin) has the highest response rate; carboplatin is substituted for renal impairment but is inferior; complete responses are rare and OS is 12–24 months.
• Unresectable localized disease — offer a clinical trial or best supportive/palliative care (radiation, systemic, endoscopic, or ablative for refractory hematuria), with multidisciplinary input.

Patient counseling — facilitate smoking cessation (smoking predicts advanced stage, recurrence, and worse mortality). Counsel on the need for endoscopic follow-up (urothelial recurrence is common regardless of approach), stricture risk with endoscopic management, the UGN-101 obstruction warning (>44%), and the risk of post-RNU CKD/dialysis. Risk factors for post-op CKD: older age, diabetes, hypertension, male sex, obesity, tobacco, larger tumour, and post-op AKI. Refer to nephrology for eGFR <45, confirmed proteinuria, diabetics with CKD, or expected post-op eGFR <30.

Prognosis and Surveillance

Prognosis

5-year overall survival:

By grade	Survival	By stage	Survival
Grade 1–2	40–87%	Ta/T1/CIS	60–90%
Grade 3–4	0–33%	T2	43–75%
		T3	16–33%
		T4	0–5%
		N+	0–4%
		M+	0%

Prognostic factors:

• Stage — the most important factor; non–organ-confined disease (>pT2) is the strongest predictor of metastasis.
• Grade — high-grade tumours invade more and associate with CIS; stage and grade each independently predict recurrence.
• Architecture — ~85% of renal pelvic tumours are papillary; papillary lesions do better than sessile (invasion occurs in 50% of papillary vs >80% of sessile tumours).
• CIS — higher progression risk.
• Size — >3–4 cm may worsen survival and bladder-recurrence risk.
• Location — renal pelvic tumours are usually more aggressive (50–60% invasive) than ureteral; the renal parenchyma may slow spread of T3 pelvic tumours, whereas periureteral extension disseminates early (evidence is conflicting overall).
• Multifocality — ≥2 urothelial sites; an independent predictor of poor outcome.
• Lymph node involvement, lymphovascular invasion (worse in node-negative disease), hydronephrosis, positive margins, and prior/concomitant bladder tumours.
• Patient/surgical factors — increasing age, Black non-Hispanic race, and lack of post-op MMC instillation. The aristolochic-acid, analgesic-abuse, and Lynch-associated forms have a higher tendency to multiple/bilateral recurrence.

Surveillance

Surveillance aims to detect urothelial recurrences, de novo urinary-tract tumours, and regional/distant metastases early. After nephron-sparing surgery most patients develop ipsilateral upper-tract recurrence (proximal-to-distal field change, more pronounced than in the bladder).

• Intravesical recurrence — ~30% develop bladder cancer after RNU or nephron-sparing surgery, mostly within 2 years (median 6–12 months). Risk factors include male sex, previous bladder cancer, preoperative CKD, positive preoperative cytology, ureteral tumour size, multifocality, invasive T-stage, necrosis, laparoscopic approach, extravesical bladder-cuff removal, positive margins, and prior ureteroscopic biopsy.
• Contralateral recurrence — ~2%.
• Distant metastasis — ~16% after RNU (median 13–16 months): lung 5%, bone 4%, liver 4%; brain rare (image promptly for neurologic symptoms).

Post-operative evaluation routinely includes cystoscopy (bladder), upper-tract endoscopy and imaging (CT urography preferred; MR urography/retrograde if contrast contraindicated) of the ipsilateral (if organ-sparing) and contralateral tracts, urine cytology, and chest imaging (CXR or CT).

AUA schedule (abbreviated):

• After kidney-sparing, low-risk — cystoscopy + upper-tract endoscopy at 1–3 months to confirm treatment; then cystoscopy within the first year and ≥6–9 monthly for 2 years then annually; upper-tract endoscopy at 6 and 12 months; upper-tract imaging ≥6–9 monthly for 2 years then annually to 5 years; no distant evaluation.
• After kidney-sparing, high-risk — as above plus cytology, with cystoscopy/cytology every 3–6 months for 3 years then 6–12 monthly to 5 years, upper-tract imaging + BMP every 3–6 months for 3 years, and chest imaging every 6–12 months to 5 years.
• After RNU, <pT2 N0/M0 — cystoscopy + cytology at 3 months then by grade (LG ≥5–9 monthly ×2 years then annually; HG every 3–6 months ×3 years then annually); abdomen/pelvis imaging within 6 months then annually ≥5 years (~5% contralateral risk).
• After RNU, T2+ — cystoscopy + cytology at 3 months then every 3–6 months ×3 years then annually; contrast CT urography of abdomen/pelvis every 3–6 months years 1–2, every 6 months year 3, then annually to 5; chest CT every 6–12 months for 5 years.

CUA schedule — cytology + cystoscopy at months 3, 6, 12, 18, 24 then annually to 10 years; ipsilateral upper tract by URS + selective cytology/biopsy on the same schedule after nephron-sparing surgery; abdomen/pelvis CT urography, CXR, and bone scan (if indicated) for distant sites. High-grade/pT≥2/pN+ warrant lifelong annual surveillance; low-grade pT<2 may be discharged after 10 recurrence-free years.

Sequelae of nephroureterectomy — reassess blood pressure, eGFR, and proteinuria soon after surgery and at 3–6 months for CKD development/progression (hyperfiltration can damage remaining nephrons). Optimize diabetes/hypertension control and smoking cessation, avoid nephrotoxins, and refer to nephrology for progressive insufficiency or proteinuria. Survivorship — encourage smoking cessation, exercise, and a healthy diet; UTUC associates with metabolic syndrome and obesity, which worsen outcomes.